Staphylococcus aureus is responsible for a multitude of infections ranging from skin and soft tissue infections to more severe invasive diseases. In response to S. aureus, host defense peptides (HDPs) are produced as nature’s own sentinel effector molecules. HDPs are small, often cationic, molecules that possess numerous biological activities, such as antimicrobial activity, cellular recruitment, anti-inflammatory properties, and wound healing, all of which play a role in controlling S. aureus infections. In hopes of capitalizing on the powerful anti-infective functions of HDPs, there has been a considerable amount of interest in deriving HDP-based therapeutics. Here, we highlight current advancements in HDP research, constraints to commercial development, and solutions for safer and more feasible HDP-based therapies against S. aureus.
|Title of host publication||Host Defense Peptides and Their Potential as Therapeutic Agents|
|Publisher||Springer International Publishing|
|Number of pages||21|
|Publication status||Published - 1 Jan 2016|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Immunology and Microbiology(all)